Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have signed a written agreement to take part in the study before it begins.
- People who have been diagnosed with relapsing multiple sclerosis (MS) according to a standard set of medical guidelines (McDonald Criteria, 2017), and whose first MS symptoms appeared less than 5 years before starting the medication ofatumumab (also known as Kesimpta).
- People who have been taking ofatumumab for at least 3 months, but no longer than 6 months, before joining the study.
- People whose ofatumumab treatment follows the approved European prescribing guidelines for Kesimpta — meaning adults with a relapsing form of MS that is showing signs of active disease based on symptoms or brain scans.
- People who have had at least one brain MRI scan taken at least 3 months after starting ofatumumab, or whose doctor already plans (as part of their normal care, unrelated to this study) to perform such a scan within 31 days of joining the study (confirm with trial site for specific MRI requirements).
- People who are willing and able to complete all study assessments, including questionnaires about their health and wellbeing, as required by the study.
Who may not be able to join:
- People who have used an experimental (investigational) drug during the study period, between starting ofatumumab and joining the study, within 3 months before starting ofatumumab, or within a certain timeframe based on how long the experimental drug stays active in the body — whichever period is longest (confirm with trial site for specific timing details).
- People who are currently pregnant, planning to become pregnant during the study period, or who are breastfeeding or lactating.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: +41613241111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of patients with no evidence of disease activity (NEDA-3) compared to SoC arm of STHENOS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.